Advertisement
Screener

ENDRA LIFE SCIENCES INC. (NDRA) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period

2.8 / 5 stars · 68/120 Roast Me

ENDRA LIFE SCIENCES INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period

ENDRA LIFE SCIENCES INC. (NDRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 0 shares for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-14.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2020-08-14

  • ENDRA LIFE SCIENCES INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2020-06-30 was 0.00 shares.
  • ENDRA LIFE SCIENCES INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2020-03-31 was 0.00 shares.
  • ENDRA LIFE SCIENCES INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2019-12-31 was 0.00 shares.
  • ENDRA LIFE SCIENCES INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2019-09-30 was 0.00 shares.
  • ENDRA LIFE SCIENCES INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2019 was 0.00 shares.
  • ENDRA LIFE SCIENCES INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2018 was 0.00 shares.
  • ENDRA LIFE SCIENCES INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2017 was 0.00 shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month
2020-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14
0.00 shares
10-Q · filed 2020-08-14
0.00 shares
derived: sum of 3 quarters · filed 2020-08-14
0.00 shares
derived: sum of 4 quarters · filed 2020-08-14
2020-03-310.00 shares
10-Q · filed 2020-05-14
0.00 shares
derived: sum of 2 quarters · filed 2020-05-14
0.00 shares
derived: sum of 3 quarters · filed 2020-05-14
0.00 shares
derived: sum of 4 quarters · filed 2020-05-14
2019-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26
0.00 shares
derived: sum of 2 quarters · filed 2020-03-26
0.00 shares
derived: sum of 3 quarters · filed 2020-03-26
0.00 shares
10-K · filed 2020-03-26
2019-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13
0.00 shares
derived: sum of 2 quarters · filed 2019-11-13
0.00 shares
10-Q · filed 2019-11-13
0.00 shares
derived: sum of 4 quarters · filed 2019-11-13
2019-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
0.00 shares
10-Q · filed 2019-08-08
0.00 shares
derived: sum of 3 quarters · filed 2019-08-08
0.00 shares
derived: sum of 4 quarters · filed 2019-08-08
2019-03-310.00 shares
10-Q · filed 2019-05-14
0.00 shares
derived: sum of 2 quarters · filed 2019-05-14
0.00 shares
derived: sum of 3 quarters · filed 2019-05-14
0.00 shares
derived: sum of 4 quarters · filed 2019-05-14
2018-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11
0.00 shares
derived: sum of 2 quarters · filed 2019-03-11
0.00 shares
derived: sum of 3 quarters · filed 2019-03-11
0.00 shares
10-K · filed 2019-03-11
2018-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05
0.00 shares
derived: sum of 2 quarters · filed 2018-11-05
0.00 shares
10-Q · filed 2018-11-05
0.00 shares
derived: sum of 4 quarters · filed 2018-11-05
2018-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13
0.00 shares
10-Q · filed 2018-08-13
0.00 shares
derived: sum of 3 quarters · filed 2018-08-13
0.00 shares
derived: sum of 4 quarters · filed 2018-08-13
2018-03-310.00 shares
10-Q · filed 2018-05-15
0.00 shares
derived: sum of 2 quarters · filed 2018-05-15
0.00 shares
derived: sum of 3 quarters · filed 2018-05-15
0.00 shares
derived: sum of 4 quarters · filed 2018-05-15
2017-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20
0.00 shares
derived: sum of 2 quarters · filed 2018-03-20
0.00 shares
derived: sum of 3 quarters · filed 2018-03-20
0.00 shares
10-K · filed 2018-03-20
2017-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14
0.00 shares
derived: sum of 2 quarters · filed 2017-11-14
0.00 shares
10-Q · filed 2017-11-14
2017-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
0.00 shares
10-Q · filed 2017-08-07
2017-03-310.00 shares
10-Q · filed 2017-06-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
IRIDEX CORP (IRIX)United States$0.011B
Nuwellis, Inc. (NUWE)United States$0.003B
QT IMAGING HOLDINGS, INC. (QTI)United States$0.037B
PRECISION OPTICS CORPORATION, INC. (POCI)United States$0.052B
Outset Medical, Inc. (OM)United States$0.059B-1.09
Streamex Corp. (STEX)United States$0.089B-0.19
Nexalin Technology, Inc. (NXL)United States$0.094B
Neuraxis, INC (NRXS)United States$0.097B
electroCore, Inc. (ECOR)United States$0.102B
Vivani Medical, Inc. (VANI)United States$0.111B